Prostate cancer is one of the leading causes of death for men in America as approximately 1 in 41 men will have prostate cancer. In this research, we focus on enzalutamide-resistant prostate cancer cells as cell resistance to enzalutamide is a prevalent obstacle in treating prostate cancer. We tested a novel compound library at different doses and observed each compound's efficacy in inducing apoptosis in enzalutamide-resistant cells. Furthermore, we analyzed the mechanism by which apoptosis was induced in compounds that showed a high efficacy at lower doses. Overall, we found that Darapladib shows promising results in treating cells that have acquired enzalutamide resistance.
Bachelor of Science (B.S.)
College of Medicine
Burnett School of Biomedical Sciences
Sanghvi, Parshva A., "A Novel Drug to Induce Apoptosis in Advanced Prostate Cancer Cells" (2022). Honors Undergraduate Theses. 1202.